Eli Lilly's stock tumbled 8% on Tuesday after it forecast fourth-quarter sales of weight-loss drug Zepbound below Wall Street ...

Eli Lilly & Co. (LLY) shares rose 0.3% premarket Wednesday, bouncing slightly after Tuesday's steep 6% plunge — the worst ...

Unfortunately for the company, however, the early glimpse at its fourth-quarter performance doesn’t seem to be going over ...

JPM25 is in full swing as several pharma powerhouses—including Merck, Lilly and Amgen—detail their strategies for growth in ...

Eli Lilly’s CEO Dave Ricks cited stocking levels and unexpected market dynamics in Q4 2024 in the GLP-1RA market.

Eli Lilly said on Monday it has sued two medical spas for selling unapproved products claiming to contain tirzepatide, the ...

Eli Lilly agreed to acquire Scorpion Therapeutics’ breast cancer treatment program for up to $2.5 billion in cash.

Eli Lilly cut its outlook for fourth-quarter revenue citing sluggish growth in the market for incretin, which increases ...

The pharma will spend up to $2.5 billion to acquire an experimental PI3K inhibitor from Scorpion, which will spin out a new ...

Eli Lilly shares could remain under the microscope on Wednesday after falling sharply Tuesday as the pharmaceutical giant ...

Eli Lilly has been operating a global capability center (GCC) in Bengaluru, India. | For nearly a decade, Eli Lilly has been ...

After selling its PI3Kα program to Eli Lilly, Scorpion will spinout out a different entity, which will be owned by the ...